Jose Hernandez, MD
Gastroenterology · Myrtle Beach, SCNPI 1578755773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 577 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 37.7% of the total. Reporting peaked in 2022 at $2,188 and has fallen 62.4% since, to $823 in 2025.
Across 577 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$658
- Johnson & Johnson$655
- Ironwood Pharmaceuticals, Inc$463
- Bristol Myers Squibb$455
- plus $3K from 30 others
Across 5 payments — averaging $8236.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$41K
What the payments were for
- Food & beverage$9,57799%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 225 | $3,646 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 77 | $1,089 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $658 |
| Johnson & Johnson | 38 | $655 |
| Ironwood Pharmaceuticals, Inc | 28 | $463 |
| Bristol Myers Squibb | 36 | $455 |
| Gilead | 19 | $398 |
| Pfizer | 20 | $359 |
| Sanofi | 12 | $302 |
| Regeneron Healthcare Solutions, Inc. | 8 | $190 |
| Daiichi Sankyo Inc. | 10 | $164 |
| Nestle Healthcare Nutrition Inc. | 7 | $138 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Ardelyx, Inc. | 7 | $114 |
| Lilly USA, LLC | 6 | $111 |
| Merck | 8 | $110 |
| QOL Medical, LLC | 6 | $107 |
| Ferring Pharmaceuticals Inc. | 6 | $87 |
| Phathom Pharmaceuticals, Inc. | 5 | $66 |
| Intercept Pharmaceuticals, Inc. | 4 | $56 |
| Abbott | 2 | $46 |
| Boston Scientific | 3 | $42 |
| Amgen | 2 | $37 |
| Medtronic | 2 | $35 |
| CSL Behring | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Intra-sana Laboratories | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Axonics, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,677 in reported general payments places this provider in the 80th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $596,828 |
| Humira(Cf) PenAdalimumab | 18 | $122,117 |
| LinzessLinaclotide | 30 | $23,888 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 32 | $5,515 |
| Pantoprazole Sodium | 305 | $4,981 |
| Dexlansoprazole DrDexlansoprazole | 11 | $4,758 |
| Omeprazole | 166 | $2,353 |
| Dicyclomine Hcl | 107 | $1,805 |
| Budesonide EcBudesonide | 12 | $1,532 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 73 | $1,183 |
| Ursodiol | 12 | $783 |
| Famotidine | 45 | $749 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 34 | $559 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 33 | $367 |
| Ondansetron Hcl | 33 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $655 | $596,82822 claims |
| AbbVieLinzess | $3,646 | $23,88830 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $87 | $5,51532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 259 gastroenterology providers in South Carolina.
Other gastroenterology in Myrtle Beach
- Andrew PearsonMyrtle Beach$166K
- Kathleen RaynorMyrtle Beach$25K
- Timothy CornnellMyrtle Beach$9K
- Erin ForsterCharleston$788K
- Mark DeleggeCharleston$568K
- Nathan ShoresCharleston$217K
- Andre EaddyGreenville$212K
- Alejandro SuarezCharleston$210K
- Veeral OzaGreenville$199K
- Peter CottonCharleston$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.